%0 Chart or Table
%A Arnoux, Isabelle
%A Willam, Michael
%A Griesche, Nadine
%A Krummeich, Jennifer
%A Watari, Hirofumi
%A Offermann, Nina
%A Weber, Stephanie
%A Narayan Dey, Partha
%A Chen, Chen
%A Monteiro, Olivia
%A Buettner, Sven
%A Meyer, Katharina
%A Bano, Daniele
%A Radyushkin, Konstantin
%A Langston, Rosamund
%A Lambert, Jeremy J.
%A Wanker, Erich
%A Methner, Axel
%A Krauss, Sybille
%A Schweiger, Susann
%A Stroh, Albrecht
%T Dataset: Data from: Metformin reverses early cortical network dysfunction and behavior changes in Huntington’s disease
%I Dryad
%M DZNE-2022-01789
%D 2018
%X Catching primal functional changes in early, “very far from disease onset” (VFDO) stages of Huntington’s disease is likely to be the key to a successful therapy. Focusing on VFDO stages, we assessed neuronal microcircuits in premanifest Hdh150 knock-in mice. Employing in vivo two-photon Ca2+ imaging, we revealed an early pattern of circuit dysregulation in the visual cortex- one of the first regions affected in premanifest Huntington’s disease - characterized by an increase in activity, an enhanced synchronicity and hyperactive neurons. These findings are accompanied by aberrations in animal behavior. We furthermore show that the anti-diabetic drug metformin diminishes aberrant Huntingtin protein load and fully restores both, early network activity patterns and behavioral aberrations. This network-centered approach reveals a critical window of vulnerability far before clinical manifestation and establishes metformin as a promising candidate for a chronic therapy starting early in premanifest Huntington’s disease pathogenesis long before the onset of clinical symptoms.
%K cortical microcircuits (Other)
%K Huntington disease (Other)
%K in vivo calcium imaging (Other)
%K metformin (Other)
%K neuronal hyperactivity (Other)
%F PUB:(DE-HGF)32
%9 Dataset
%R 10.5061/dryad.g3b5272
%U https://pub.dzne.de/record/169082